Q-Line Biotech Ltd H1 FY27 Revenue Reaches ₹152 Crore, Up 5.8%
Key highlights
- Q-Line Biotech reported H1 FY27 consolidated revenue of ₹152.2 crore, up 5.8% year on year.
- EBITDA rose 10.0% to ₹39.57 crore and the EBITDA margin was 26.0%.
- Consolidated profit after tax fell 8.0% to ₹19.6 crore as depreciation increased and a tax writeback did not recur.
- Instrument revenue declined 29%, while reagents and trade grew around 19% to 20%.
powered by IRIS

Q-Line Biotech Ltd reported H1 FY27 revenue of ₹152.2 crore, up 5.8% year on year. Consolidated net profit declined 8.0% to ₹19.6 crore despite a 10.0% rise in EBITDA, as higher depreciation and the absence of a prior tax writeback affected the bottom line.
Know Q-Line Biotech inside out
Results, valuation, peers and who's buying, in one view.
What were Q-Line Biotech's H1 FY27 financial results?
Q-Line Biotech reported consolidated revenue from operations of ₹152.2 crore for the half year ended September 30, 2026, compared with ₹143.6 crore in the corresponding period a year earlier. The increase was 5.8% year on year. Consolidated EBITDA rose 10.0% to ₹39.57 crore, and the EBITDA margin was 26.0%.
Consolidated profit after tax was ₹19.6 crore, down 8.0% from the prior-year period. Separately, the company reported standalone revenue of ₹152.1 crore and standalone net profit of ₹20.2 crore, compared with ₹143.6 crore and ₹21.5 crore, respectively, a year earlier. The difference between standalone and consolidated profit reflects the separate reporting bases disclosed by the company.
Why did Q-Line Biotech's profit decline despite EBITDA growth?
Q-Line Biotech's consolidated profit declined because higher depreciation and the non-recurrence of a tax writeback weighed on the reported bottom line. The company nevertheless recorded EBITDA growth ahead of revenue growth, with operating profit rising 10.0% while revenue increased 5.8%.
The disclosed 26.0% EBITDA margin indicates that operating profitability remained stronger than the movement in net profit alone suggests. However, profit after tax is affected by items beyond operating performance, including depreciation and tax-related adjustments. Investors therefore need to distinguish between the improvement in EBITDA and the decline in reported net profit during the half year.
What caused the slower revenue growth in H1 FY27?
The slower revenue growth was linked to a 29% decline in instrument revenue after delays in government execution. Management said growth in reagents and trade, at around 19% to 20%, partly offset the fall in instruments, but was not sufficient to lift overall revenue growth to the level implied by those segments.
Government-linked instrument orders can affect the timing of revenue recognition when execution is delayed. The company did not disclose in the provided material the value of delayed orders, the number of affected contracts, or a date for their execution. Its H1 performance therefore reflected a different mix, with recurring reagent and trade activity supporting growth while instrument revenue was weaker.
Management lowered its FY27 growth outlook to 25% to 30% after the first-half results and indicated a similar growth rate for FY28. It cited expectations of a stronger second half, new products and CDMO activity, but the company did not provide a detailed quarterly revenue target in the supplied disclosures.
Got a follow-up? Ask IRIS
What is Q-Line Biotech doing with its IPO funds and Heidelco investment?
Q-Line Biotech's board approved the acquisition of a 70% stake in group company Heidelco Medicore at net asset value. The company also identified the ramp-up of Unit 4 and the Heidelco acquisition as strategic priorities in its investor presentation.
Of the ₹214.48 crore IPO proceeds, Q-Line Biotech stated that ₹122.3 crore had been used. This included ₹89.9 crore used mainly for debt repayment. The company said ₹92.1 crore remained in bank deposits, based on the figures disclosed with the H1 results.
How do the H1 results affect Q-Line Biotech investors?
The H1 results show that Q-Line Biotech maintained revenue growth and improved EBITDA even as instrument sales weakened and consolidated profit declined. For investors, the main operating data points are the 29% fall in instruments, growth of around 19% to 20% in reagents and trade, and the 26.0% EBITDA margin.
The revised FY27 growth outlook of 25% to 30% places attention on the pace of government order execution in the second half. Unit 4 ramp-up, new products, CDMO activity and the planned Heidelco Medicore acquisition are also relevant to the company's operating plan. The disclosures do not provide a forecast for net profit, margin changes or the financial contribution from Heidelco.
Conclusion
Q-Line Biotech delivered H1 FY27 consolidated revenue of ₹152.2 crore and EBITDA growth of 10.0%, but its consolidated profit after tax fell to ₹19.6 crore. Delayed government execution reduced instrument revenue, while reagent and trade growth provided partial support to the overall revenue base.
The next disclosures to watch are progress in government instrument execution, the second-half delivery needed to support the 25% to 30% FY27 growth outlook, and updates on Unit 4 and the 70% Heidelco Medicore acquisition. Investors can also track further deployment of the ₹92.1 crore held in bank deposits from IPO proceeds.


